Abstract: A manufacture method of a deodorization fiber includes: a mixing step including mixing zirconium phosphate and a first dispersant including an amine-group compound in a solvent to form a mixture; a grinding step including grinding the mixture until a D90 particle size of zirconium phosphate is 0.1 ?m to 1.5 ?m to form a grinded mixture; a heating and stirring step including heating and stirring the grinded mixture to uniformly distribute zirconium phosphate and the first dispersant in the solvent to form a deodorant; a blending and pelletizing step including blending and pelletizing the deodorant and polyester to form a fiber masterbatch; and a melt spinning step including melt spinning the fiber masterbatch to form the deodorization fiber. A deodorization fiber is further provided.

Abstract: A semiconductor device comprises a fin structure disposed over a substrate; a gate structure disposed over part of the fin structure; a source/drain structure, which includes part of the fin structure not covered by the gate structure; an interlayer dielectric layer formed over the fin structure, the gate structure, and the source/drain structure; a contact hole formed in the interlayer dielectric layer; and a contact material disposed in the contact hole. The fin structure extends in a first direction and includes an upper layer, wherein a part of the upper layer is exposed from an isolation insulating layer. The gate structure extends in a second direction perpendicular to the first direction. The contact material includes a silicon phosphide layer and a metal layer.

Abstract: A method of manufacturing a semiconductor device includes forming a plurality of fin structures extending in a first direction over a semiconductor substrate. Each fin structure includes a first region proximate to the semiconductor substrate and a second region distal to the semiconductor substrate. An electrically conductive layer is formed between the first regions of a first adjacent pair of fin structures. A gate electrode structure is formed extending in a second direction substantially perpendicular to the first direction over the fin structure second region, and a metallization layer including at least one conductive line is formed over the gate electrode structure.

Abstract: A cell-nanoparticle drug delivery system includes mesenchymal stem cells and gadolinium-based agent-loaded magnetic nanoparticles which are internalized into the mesenchymal stem cells. Each of the gadolinium-based agent-loaded magnetic nanoparticles includes a core that is loaded with gadolinium-based agent and that includes a fucoidan-based inner core layer with the fucoidan non-covalently bound to the gadolinium-based agent, and a shell which includes superparamagnetic iron oxide-based inner shell layer with the superparamagnetic iron oxide bound to the gadolinium-based agent through electrical attraction, and an outer shell layer made of fucoidan and polyvinyl alcohol. Methods for inhibiting the growth of tumor cells and diagnosing the tumor cells in a subject using the cell-nanoparticle drug delivery system are also provided.

Abstract: The present disclosure provides a nanocapsule comprising a hydrophilic core; and a hydrophobic shell enclosing the hydrophilic core. The hydrophobic shell contains an outer layer comprising fucoidan, a middle layer comprising carotenoids and metal oxide nanoparticles, and an inner layer comprising fucoidan and contacting the hydrophilic core. The present disclosure also provides use of the nanocapsule as disclosed herein in the manufacture of a medicament for treating and/or diagnosing diseases in a subject in need thereof.

Abstract: An immunomagnetic nanocapsule includes a core, a shell and an outer layer. The shell is formed by a complex, and the complex is fabricated by a combination of fucoidan, oxidized dextran, and a plurality of superparamagnetic iron oxide nanoparticles via a hydrophobic interaction. The core is encapsulated in the shell. The outer layer includes at least one antibody immobilized to outside of the shell to form the outer layer, wherein the antibody is an immune checkpoint inhibitor and/or a T cell expansion antibody.

Abstract: An immunomagnetic nanocapsule includes a core, a shell and an outer layer. The shell is formed by a complex, and the complex is fabricated by a combination of fucoidan, oxidized dextran, and a plurality of superparamagnetic iron oxide nanoparticles via a hydrophobic interaction. The core is encapsulated in the shell. The outer layer includes at least one antibody immobilized to outside of the shell to form the outer layer, wherein the antibody is an immune checkpoint inhibitor and/or a T cell expansion antibody.

Abstract: An antibody-conjugated double-emulsion nanocapsule is provided. A linking group is introduced on the surface of a double-emulsion nanocapsule, which is composed of an oily shell enclosing an aqueous core, to link the double-emulsion nanocapsule with an antibody.

Abstract: The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.

Abstract: A drug carrier includes an aqueous solution, a protein shell, graphenes, and a bioactive agent. The protein shell encloses the aqueous solution, and includes at least one hydrophilic/hydrophobic layer. The graphenes are dispersed in the protein shell, and the bioactive agent is in the aqueous solution and/or the protein shell.

Abstract: A method is provided for detecting the presence of nucleotides or monitoring nucleotide amplification. It utilizes fluorescence energy transfer by competitive hybridization. Competitive hybridization is achieved by using unequal length complementary probes which have a fluorophore on one probe and a quencher on the other. The fluorophore and quencher are juxtaposed in a manner wherein the proximity of the quencher to the fluorophore produces quenching of the fluorescence of the fluorophore.

Abstract: The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.

Abstract: An antibody-conjugated double-emulsion nanocapsule is provided. A linking group is introduced on the surface of a double-emulsion nanocapsule, which is composed of an oily shell enclosing an aqueous core, to link the double-emulsion nanocapsule with an antibody.

Abstract: The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.

Abstract: A method is provided for detecting the presence of nucleotides or monitoring nucleotide amplification. It utilizes fluorescence energy transfer by competitive hybridization. Competitive hybridization is achieved by using unequal length complementary probes which have a fluorophore on one probe and a quencher on the other. The fluorophore and quencher are juxtaposed in a manner wherein the proximity of the quencher to the fluorophore produces quenching of the fluorescence of the fluorophore.

Abstract: A method is provided for detecting the presence of nucleotides or monitoring nucleotide amplification. It utilizes fluorescence energy transfer by competitive hybridization. Competitive hybridization is achieved by using unequal length complementary probes which have a fluorophore on one probe and a quencher on the other. The fluorophore and quencher are juxtaposed in a manner wherein the proximity of the quencher to the fluorophore produces quenching of the fluorescence of the fluorophore.

Abstract: The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.

Abstract: Disclosed herein are methods for matching a cancer condition with an appropriate immunotherapeutic agent and/or regimen. Also disclosed are methods for confirming diagnosis of a particular type of cancer. Embodiments of the invention disclosed herein are directed to the use of effective combinations of TuAAs to optimize the match between a patient's cancer condition and available immunotherapies.

Abstract: The present invention provides a method of treating a cell proliferative disease such as cancer by providing to a subject in need thereof an immunogenic composition comprising plasmid and peptide(s) or analogues thereof. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.

Abstract: A method is provided for detecting the presence of nucleotides or monitoring nucleotide amplification. It utilizes fluorescence energy transfer by competitive hybridization. Competitive hybridization is achieved by using unequal length complementary probes which have a fluorophore on one probe and a quencher on the other. The fluorophore and quencher are juxtaposed in a manner wherein the proximity of the quencher to the fluorophore produces quenching of the fluorescence of the fluorophore.